Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Frequency, Clinical Pattern and Outcome of Thrombosis in Cancer Patients in Saudi Arabia

  • Aleem, Aamer (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) ;
  • Diab, Abdul Rahman Al (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) ;
  • Alsaleh, Khalid (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) ;
  • Algahtani, Farjah (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) ;
  • Alsaeed, Eyad (Department of Medicine, Division of Hematology/Oncology, College of Medicine and King Khalid University Hospital, King Saud University) ;
  • Iqbal, Zafar (Department of Pathology, College of Medicine and King Khalid University Hospital, King Saud University) ;
  • El-Sherkawy, Mohamed Sherif (Department of Radiology, College of Medicine and King Khalid University Hospital, King Saud University)
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Thrombotic risk is increased in patients with cancer and there are important implications for those who suffer a venous thromboembolism (VTE). We undertook this study to determine the frequency, clinical patterns, and outcome of VTE in Saudi patients with cancer. Methods: Cancer (solid tumors and lymphoma) patients who developed VTE from January 2004 to January 2009 were studied retrospectively. Demographics and clinical characteristics related to thrombosis and cancer were evaluated. Results: A total of 701 patients with cancer were seen during the study period. VTE was diagnosed in 47 (6.7%) patients (median age 52, range 18-80 years). Lower limb DVT was the most common type, seen in 47% patients, followed by PE in 19%, and 19% patients had both DVT & PE. Thrombosis was symptomatic in 72% patients while it was an incidental finding on routine workup in 28%. Cancer and VTE were diagnosed at the same time in 38% of patients, and 47% patients developed VTE during the course of disease after the cancer diagnosis. The majority of VTE post cancer diagnoses occurred during the first year (median 4 months, range 1-14). Additional risk factors for VTE were present in 22 (47%) patients and 14 (30%) of these patients were receiving chemotherapy at the time of thrombosis. Only 5 (10.6%) patients were receiving thrombo-prophylaxis at the time of VTE diagnosis. Most common types of tumors associated with thrombosis were breast cancer, non-Hodgkin's lymphoma and lung cancer. The majority of the affected patients (79%) had advanced stage of cancer. After a median follow-up of 13 (range 0.5-60) months, 38 (81%) patients had died. There was no difference in the mortality of patients with symptomatic or asymptomatic thrombosis (82% vs 78.6%). Conclusions: Thrombotic complications can develop in a significant number of patients with cancer, and almost half of the patients have additional risk factors for VTE. Thrombosis is usually associated with advanced disease and can be asymptomatic in more than a quarter of cases. Thromboprophylaxis in cancer patients is under-utilized. Community based studies are needed to accurately define the extent of this problem and to develop effective prophylactic strategies.

Keywords

References

  1. Abba AA, Al Ghonaim MA, Rufai AM (2004). Physicians' practice for prevention of venous thromboembolism in medical patients. J Coll Physicians Surg Pak, 14, 211-4.
  2. Agnelli G, George DJ, Kakkar AK, et al (2012). SAVE-ONCO Investigators (2012). Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med, 366, 601-9. https://doi.org/10.1056/NEJMoa1108898
  3. Al Diab AI (2010). Cancer-related venous thromboembolism: insight into underestimated risk facrors. Hematol Oncol Stem Cell Ther, 3, 191-5. https://doi.org/10.5144/1658-3876.2010.191
  4. Amin A, Stemkowski S, Lin J, Yang G (2008). Appropriate thromboprophylaxis in hospitalized cancer patients. Clin Adv Hematol Oncol, 6, 910-20.
  5. Beck-Razi N, Kuzmin A, Koren D, (2010). Asymptomatic deep vein thrombosis in advanced cancer patients: the value of venous sonography. J Clin Ultrasound, 38, 232-7.
  6. Chew HK, Davies AM, Wun T, et al (2008). The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost, 6, 601-8. https://doi.org/10.1111/j.1538-7836.2008.02908.x
  7. Chew HK, Wun T, Harvey D, Zhou H, White RH (2006). Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med, 166, 458-64. https://doi.org/10.1001/archinte.166.4.458
  8. Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM (2007). Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. Am J Roentgenol, 189, 162-70. https://doi.org/10.2214/AJR.07.2067
  9. Elting LS, Escalante CP, Cooksley C, et al (2004). Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med, 164, 1653-61. https://doi.org/10.1001/archinte.164.15.1653
  10. Engelke C, Rummeny EJ, Marten K (2006). Pulmonary embolism at multi-detector row CT of chest: 1-year survival of treated and untreated patients. Radiology, 239, 563-75. https://doi.org/10.1148/radiol.2392050118
  11. Gladish GW, Choe DH, Marom EM, et al (2006). Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology, 240, 246-55. https://doi.org/10.1148/radiol.2401051129
  12. Goldhaber SZ, Tapson VF (2004). DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol, 93, 259-62. https://doi.org/10.1016/j.amjcard.2003.09.057
  13. Gomes MP, Deitcher SR (2003). Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Williston Park, NY), 17:126-35, 139; discussion 139-44.
  14. Gross CP, Galusha DH, Krumholz HM (2007). The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. J Gen Intern Med, 22, 321-6. https://doi.org/10.1007/s11606-006-0019-x
  15. Heidrich H, Konau E, Hesse P (2009). Asymptomatic venous thrombosis in cancer patients-a problem often overlooked. Results of a retrospective and prospective study. Vasa, 38, 160-6. https://doi.org/10.1024/0301-1526.38.2.160
  16. Imberti D, Agnelli G, Ageno W, et al (2008). MASTER Investigators. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica, 93, 273-8. https://doi.org/10.3324/haematol.11458
  17. Keenan CR, White RH (2007). The effects of race/ethnicity and sex on the risk of venous thromboembolism. Curr Opin Pulm Med, 13, 377-83.
  18. Khorana AA, Streiff MB, Farge D (2009). Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol, 27, 4919-26. https://doi.org/10.1200/JCO.2009.22.3214
  19. Khorana AA, Connolly GC (2009). Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol, 27, 4839-47. https://doi.org/10.1200/JCO.2009.22.3271
  20. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008). Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood, 111, 4902-7. https://doi.org/10.1182/blood-2007-10-116327
  21. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007). Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost, 5, 632-4. https://doi.org/10.1111/j.1538-7836.2007.02374.x
  22. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007). Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer, 110, 2339-46. https://doi.org/10.1002/cncr.23062
  23. Klatsky AL, Armstrong MA, Poggi J (2000). Risk of pulmonary embolism and/or deep venous thrombosis in Asian- Americans. Am J Cardiol, 85, 1334-7. https://doi.org/10.1016/S0002-9149(00)00766-9
  24. Kroger K, Weiland D, Ose C, et al (2006). Risk factors for venous thromboembolic events in cancer patients. Ann Oncol, 17, 297-303.
  25. Monreal M, Falga C, Valdes M, et al (2006). Riete Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost, 4, 1950-6. https://doi.org/10.1111/j.1538-7836.2006.02082.x
  26. O'Connell CL, Ghalichi M, Boyle S (2008). Unsuspected pulmonary emboli identified on routine cancer staging MDCT scans: Impact on cancer survival. Blood, 112, 3818. https://doi.org/10.1182/blood-2008-02-138933
  27. O'Connell CL, Boswell WD, Duddalwar V, et al (2006). Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol, 24, 4928-32. https://doi.org/10.1200/JCO.2006.06.5870
  28. Ogren M, Bergqvist D, Wahlander K, Eriksson H, Sternby NH (2006). Trousseau's syndrome - what is the evidence? A population-based autopsy study. Thromb Haemost, 95, 541-5.
  29. Otten HM, Mathijssen J, Ten Cate H, et al (2004). Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med, 164, 190-4. https://doi.org/10.1001/archinte.164.2.190
  30. Ottinger H, Belka C, Kozole G, et al (1995). Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: Incidence, causes and prognostic relevance. Eur J Haematol, 54, 186-94.
  31. Prandoni P, Lensing AW, Piccioli A, et al (2002). Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood, 100, 3484-8. https://doi.org/10.1182/blood-2002-01-0108
  32. Rashid ST, Thursz MR, Razvi NA, et al (2005). Venous thromboprophylaxis in UK medical inpatients. J R Soc Med, 98, 507-12. https://doi.org/10.1258/jrsm.98.11.507
  33. Rita Larici R, Calandriello L, Maggi F (2007). Prevalence of incidental pulmonary emboli in oncology patients. Radiology, 245, 921-2.
  34. Sallah S, Wan JY, Nguyen NP (2002). Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost, 87, 575-9.
  35. Seddighzadeh A, Shetty R, Goldhaber SZ (2007). Venous thromboembolism in patients with active cancer. Thromb Haemost, 98, 656-61.
  36. Silverstein MD, Heit JA, Mohr DN, et al (1998). Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med, 158, 585-93. https://doi.org/10.1001/archinte.158.6.585
  37. Sleiman Zade Asfahani WH, Taher AT, Al Rahawi D, Khalil I (2005). Venous thromboembolism in cancer patients referred to the American University of Beirut-Medical Center secondary to deep vein thrombosis; occurrence and risk factors. J Thromb Thrombolysis, 20, 179-82. https://doi.org/10.1007/s11239-005-4048-9
  38. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000). Prognosis of cancers associated with venous thromboembolism. N Engl J Med, 343, 1846-50. https://doi.org/10.1056/NEJM200012213432504
  39. Vemulapalli S, Chintala L, Tsimberidou AM, et al (2009). Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. Am J Hematol, 84, 408-13. https://doi.org/10.1002/ajh.21423
  40. White RH, Zhou H, Romano PS (1998). Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med, 128, 737-40. https://doi.org/10.7326/0003-4819-128-9-199805010-00006
  41. Woller SC, Stevens SM, Jones JP, et al (2011). Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. Am J Med, 124, 947-54. https://doi.org/10.1016/j.amjmed.2011.06.004
  42. Wun T, White RH (2009). Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest, 27, 63-74. https://doi.org/10.1080/07357900802656681

Cited by

  1. A New D-dimer Cutoff Value to Improve the Exclusion of Deep Vein Thrombosis in Cancer Patients vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1655
  2. Can Megestrol Acetate Induce Thrombosis in Advanced Oncology Patients Receiving Chemotherapy? vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10165
  3. Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline vol.35, pp.2, 2017, https://doi.org/10.5144/0256-4947.2015.95